ImmunityBio's ANKTIVA® Receives Dual Saudi FDA Approvals for Lung and Bladder Cancers

summarizeSummary

ImmunityBio announced that the Saudi Food and Drug Authority (SFDA) granted accelerated approval for ANKTIVA® in metastatic non-small cell lung cancer (NSCLC) and approval for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

check_boxKey Events

• Accelerated Approval for Metastatic NSCLC

  The Saudi FDA granted accelerated approval for ANKTIVA® in combination with immune checkpoint inhibitors for metastatic non-small cell lung cancer (NSCLC) that has progressed after standard therapy. This marks the first global approval for this indication and subcutaneous administration.

• Approval for Non-Muscle Invasive Bladder Cancer

  ANKTIVA® plus Bacillus Calmette-Guérin (BCG) received approval from the Saudi FDA for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ, adding to existing approvals in the US, UK, and EU.

• Expansion into Middle East & North Africa

  ImmunityBio plans to open a regional office in Saudi Arabia and partner with Biopharma Cigalah to support commercialization and distribution across the Middle East and North Africa, addressing a significant unmet medical need.

auto_awesomeAnalysis

These dual regulatory approvals from the Saudi FDA represent a significant commercial and clinical milestone for ImmunityBio. The accelerated approval for ANKTIVA® in metastatic NSCLC is particularly impactful as it marks the first global approval for this indication and subcutaneous administration, opening a new market for a critical oncology treatment. The additional approval for BCG-unresponsive NMIBC expands the drug's market presence in a region with growing cancer incidence, building on existing approvals in other major markets. These approvals validate ImmunityBio's immunotherapy platform and are expected to contribute to future revenue growth and patient access in the Middle East and North Africa.